Skip to main content

Table 4 Clinical outcomes in the subsequent period by FVC% change group

From: Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

 

By lung-function change category (based on relative change in FVC%)a

 

Stable [A]

Marginal [B]

Significant [C]

Relative effect measure (95 % CI)

 

(N = 250)

(N = 98)

(N = 142)

[C] vs. [A]

[C] vs. [B]

[B] vs. [A]

 

12-Month IR per Patient

IRR

Rate of suspected AEx

0.26

0.47

0.74

2.87 (1.71–4.82)

1.58 (0.95–2.64)

1.82 (1.02–3.23)

 

12-Month Risk

OR

Risk of suspected AEx

19.2 %

37.1 %

50.9 %

4.37 (2.09–9.16)

1.76 (0.81–3.80)

2.49 (1.28–4.82)

Risk of progression

62.6 %

76.2 %

85.6 %

3.56 (1.66–7.64)

1.86 (0.81–4.26)

1.92 (0.91–4.04)

Mortalityb

Risk by 12 Months

HR

 Death due to any cause

6.4 %

13.1 %

28.0 %

5.05 (2.75–9.27)

1.85 (1.05–3.26)

2.73 (1.51–4.94)

 Death due to IPF

5.5 %

10.3 %

24.3 %

6.23 (2.96–13.14)

1.94 (1.01–3.70)

3.22 (1.59–6.53)

 Death due to AEx

5.0 %

9.3 %

13.1 %

3.91 (1.56–9.84)

1.22 (0.54–2.77)

3.21 (1.41–7.30)

  1. AEx acute exacerbation, IR incidence rate, IRR incidence rate ratio, OR odds ratio, HR hazard ratio
  2. aLung-function change categories were defined as the relative change in FVC% from index to approximately 6 months following IPF diagnosis. "Stable" was defined as decline <5 %. "Marginal" was defined as decline ≥5 % and <10 %, while "Significant" was defined as decline ≥10 %
  3. bKaplan-Meier survival analysis was used to estimate the risk of death by 12 months